133 related articles for article (PubMed ID: 19741564)
21. O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Watson AJ; Middleton MR; McGown G; Thorncroft M; Ranson M; Hersey P; McArthur G; Davis ID; Thomson D; Beith J; Haydon A; Kefford R; Lorigan P; Mortimer P; Sabharwal A; Hayward O; Margison GP
Br J Cancer; 2009 Apr; 100(8):1250-6. PubMed ID: 19367283
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Schraml P; von Teichman A; Mihic-Probst D; Simcock M; Ochsenbein A; Dummer R; Michielin O; Seifert B; Schläppi M; Moch H; von Moos R
Oncol Rep; 2012 Aug; 28(2):654-8. PubMed ID: 22614944
[TBL] [Abstract][Full Text] [Related]
23. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
24. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
25. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.
Middleton MR; Lunn JM; Morris C; Rustin G; Wedge SR; Brampton MH; Lind MJ; Lee SM; Newell DR; Bleehen NM; Newlands ES; Calvert AH; Margison GP; Thatcher N
Br J Cancer; 1998 Nov; 78(9):1199-202. PubMed ID: 9820180
[TBL] [Abstract][Full Text] [Related]
26. O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.
Adachi J; Mishima K; Wakiya K; Suzuki T; Fukuoka K; Yanagisawa T; Matsutani M; Sasaki A; Nishikawa R
J Neurooncol; 2012 Mar; 107(1):147-53. PubMed ID: 21968944
[TBL] [Abstract][Full Text] [Related]
27. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
[TBL] [Abstract][Full Text] [Related]
28. Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.
Jiang G; Jiang AJ; Xin Y; Li LT; Cheng Q; Zheng JN
Mol Biol Rep; 2014 Oct; 41(10):6659-65. PubMed ID: 24990698
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B
Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257
[TBL] [Abstract][Full Text] [Related]
30. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
31. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.
Middleton MR; Lee SM; Arance A; Wood M; Thatcher N; Margison GP
Int J Cancer; 2000 Nov; 88(3):469-73. PubMed ID: 11054678
[TBL] [Abstract][Full Text] [Related]
32. Genomic and molecular profiling predicts response to temozolomide in melanoma.
Augustine CK; Yoo JS; Potti A; Yoshimoto Y; Zipfel PA; Friedman HS; Nevins JR; Ali-Osman F; Tyler DS
Clin Cancer Res; 2009 Jan; 15(2):502-10. PubMed ID: 19147755
[TBL] [Abstract][Full Text] [Related]
33. Modes of actions of two types of anti-neoplastic drugs, dacarbazine and ACNU, to induce apoptosis.
Sanada M; Hidaka M; Takagi Y; Takano TY; Nakatsu Y; Tsuzuki T; Sekiguchi M
Carcinogenesis; 2007 Dec; 28(12):2657-63. PubMed ID: 17881774
[TBL] [Abstract][Full Text] [Related]
34. Expression of DNA repair proteins MSH2, MLH1 and MGMT in human benign and malignant thyroid lesions: an immunohistochemical study.
Giaginis C; Michailidi C; Stolakis V; Alexandrou P; Tsourouflis G; Klijanienko J; Delladetsima I; Theocharis S
Med Sci Monit; 2011 Feb; 17(3):BR81-90. PubMed ID: 21358597
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].
Tronov VA; Artamonov DN; Abramov ME; Gorbacheva LB; Lichinitser MR
Vopr Onkol; 2011; 57(2):165-72. PubMed ID: 21809660
[TBL] [Abstract][Full Text] [Related]
36. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Mehdorn HM
Neurol Res; 2010 Oct; 32(8):816-20. PubMed ID: 20223108
[TBL] [Abstract][Full Text] [Related]
37. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.
Sartore-Bianchi A; Pietrantonio F; Amatu A; Milione M; Cassingena A; Ghezzi S; Caporale M; Berenato R; Falcomatà C; Pellegrinelli A; Bardelli A; Nichelatti M; Tosi F; De Braud F; Di Nicolantonio F; Barault L; Siena S
Eur J Cancer; 2017 Jan; 71():43-50. PubMed ID: 27997874
[TBL] [Abstract][Full Text] [Related]
38. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
Hassel JC; Sucker A; Edler L; Kurzen H; Moll I; Stresemann C; Spieth K; Mauch C; Rass K; Dummer R; Schadendorf D
Br J Cancer; 2010 Sep; 103(6):820-6. PubMed ID: 20736948
[TBL] [Abstract][Full Text] [Related]
39. O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
Ma S; Egyházi S; Ueno T; Lindholm C; Kreklau EL; Stierner U; Ringborg U; Hansson J
Br J Cancer; 2003 Oct; 89(8):1517-23. PubMed ID: 14562026
[TBL] [Abstract][Full Text] [Related]
40. Importance of MutL homologue MLH1 and MutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer.
Erdamar S; Ucaryilmaz E; Demir G; Karahasanoglu T; Dogusoy G; Dirican A; Goksel S
World J Gastroenterol; 2007 Sep; 13(33):4437-44. PubMed ID: 17724798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
